A revolution in the management of multidrug-resistant tuberculosis

Affiliations

¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, and UCT Lung Institute and South African MRC-UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town 7935, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: keertan.dheda@uct.ac.za.
² Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Clinical Tuberculosis Unit, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.

Comment

Keertan Dheda et al. Lancet. 2022.

. 2022 Nov 26;400(10366):1823-1825.

doi: 10.1016/S0140-6736(22)02161-4. Epub 2022 Nov 8.

¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, and UCT Lung Institute and South African MRC-UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town 7935, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: keertan.dheda@uct.ac.za.
² Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Clinical Tuberculosis Unit, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.

Erratum in

Department of Error.
[No authors listed] [No authors listed] Lancet. 2022 Nov 26;400(10366):1846. doi: 10.1016/S0140-6736(22)02363-7. Epub 2022 Nov 18. Lancet. 2022. PMID: 36410362 No abstract available.

No abstract available

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.